TheEdgeResearch
Home / Stocks / AVCNF

Avicanna Inc. (AVCNF)

OTC Healthcare Drug Manufacturers - Specialty & Generic
$0.06 ▼ -1.09%
Market Cap
$8.1M
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Beta
0.33
52-Wk Range
0.05589-0.1804
CEO
Aras Azadian Mba
Country
CA
Currency
USD

Avicanna Inc. operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Toronto, ON, CA. The stock last traded at $0.06, down 1.09% on the session, giving a market capitalisation of $8.1M. On trailing twelve-month figures it carries a trailing P/E of -3.86, a net margin of -10.9%. Its beta of 0.33 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-3.86
Price / Sales
0.46
Price / Book
2.22
EV / EBITDA
-7.32
Gross margin
53.1%
Operating margin
-9.2%
Net margin
-10.9%
Return on equity
—
Debt / equity
0.05
Current ratio
1.01
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
112
IPO date
2021-01-08
Headquarters
Toronto, ON, CA
About Avicanna Inc.

Avicanna Inc., a biopharmaceutical firm headquartered in Toronto, Canada, and founded in 2016, is actively engaged in the research, development, and commercialization of scientifically validated products for both global medical and consumer health markets. The company's comprehensive scientific framework encompasses R&D and clinical trials, often undertaken in collaboration with Canadian academic and medical institutions. This effort has yielded around twenty commercialized products spanning four primary market categories. These offerings include medical and wellness items under the RHO Phyto brand, featuring cannabinoids such as CBD, CBG, and THC; CBD-infused topical and derma-cosmetic products marketed under the Pura H&W and Pura Earth labels; and bulk cannabis and hemp-derived raw materials like dried flowers, standardized seeds, full-spectrum extracts, cannabinoid distillates, and isolates, provided through the Aureus brand. Additionally, Avicanna is advancing a pharmaceutical pipeline focused on treatments for conditions including epidermolysis bullosa, dermatological ailments, chronic pain, and various neurological disorders. A notable research partnership with Dr. Christine Allen's Research Group is dedicated to developing a cannabinoid-based therapy for lung inflammation linked to COVID-19.

Comparable companies

Avicanna Inc. is most often compared with the following Healthcare names:

CAAOFCNTMFCWBHFEVRRFGBLPISCNFIZOZFMEDIFRAPHVYYRF
More research on AVCNF
AVCNF technical analysis AVCNF TheEdge Score Compare against peers
Open full interactive analysis & DCF →